Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants
Yohei Seki, Yasuo Yoshihara, Kiyoko Nojima, Haruka Momose, Shuetsu Fukushi, Saya Moriyama, Ayumi Wagatsuma, Narumi Numata, Kyohei Sasaki, Tomoyo Kuzuoka, Yoshiyuki Yato, Yoshimasa Takahashi, Ken Maeda, Tadaki Suzuki, Takuo Mizukami, Isao Hamaguchi
Topics & Concepts
ImmunogenicityVirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Booster (rocketry)Coronavirus disease 2019 (COVID-19)MedicineBooster doseTiterImmunologyAntibodyVirusPhysicsPathologyInfectious disease (medical specialty)DiseaseAstronomySARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesSARS-CoV-2 detection and testing